Open Biosystems' Open Access RNAi Program Adopted by John's Hopkins University and University of Manitoba
News Apr 24, 2007
Open Biosystems, Inc. has announced that leading research institutions across North America continue to adopt its Open Access RNAi Program.
Participation in the Open Access Programs allows all research laboratories within an institution access to its choice of Open Biosystems' portfolio of genome-wide resources including RNAi. The Open Access Program supports Open Biosystems' vision of supporting basic and medical research and reinforces its commitment to expanding access to research reagents for the life sciences community.
"Open Biosystems' Open Access Programs for RNAi and genomic resources provides a unique consolidated toolkit for murine and human gene analysis to our faculty members for defining the function, distribution and therapeutic potentials of human gene products in health and disease said Sam Kung, Assistant Professor, Department of Immunology.
“Under the support of the Dean Strategic Research Fund, we have established the Biomedical. Functionality Resource at the Faculty of Medicine, University of Manitoba to promote university-wide gene discovery and validation in multiple human disease,” Kung added.
"The Open Access Programs from Open Biosystems were created to address the key needs of our academic customers. Allowing institution-wide sharing of genome-scale resources in an organized and technically supported manner continues our commitment to facilitate genome-scale analysis at the bench top of individual scientists," said Troy Moore, Chief Technical Officer of Open Biosystems.
Open Biosystems' portfolio of RNAi resources include shRNAmir lentiviral and retroviral libraries targeting the entire human and mouse genomes, the RNAi Consortium human and mouse lentiviral shRNA libraries as well as RNAi collections targeting Drosophila, C. elegans and Zebrafish. These RNAi resources facilitate gene analysis on a genome scale.
Participation in the Open Access RNAi program provides researchers the complete and flexible access to evolving RNAi technologies.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.